Copyright
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Nov 6, 2020; 8(21): 5334-5340
Published online Nov 6, 2020. doi: 10.12998/wjcc.v8.i21.5334
Published online Nov 6, 2020. doi: 10.12998/wjcc.v8.i21.5334
Successful treatment of a high-risk nonseminomatous germ cell tumor using etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine: A case report
Jina Yun, Sung H Lim, Se H Kim, Chan K Kim, Seong K Park, Department of Internal Medicine, Division of Hematology-Oncology, Soonchunhyang University Bucheon Hospital, Soonchunhyang University School of Medicine, Bucheon 14584, South Korea
Sang W Lee, Department of Urology and Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University School of Medicine, Bucheon 14584, South Korea
Author contributions: Yun J concentualized, acquisition fund and wrote the original draft; Park SK curated, administrated project, wrote, reviewed and edited the draft; S Kim SH investigated and analyzed form; Kim CK supported the methodology and software; Lee SW support the resources and supervision; Lim SH made the validation and visualization; all authors approved of the final manuscript.
Supported by the Soonchunhyang University Research Fund , No. 20200011 .
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Seong K Park, MD, Professor, Department of Internal Medicine, Division of Hematology-Oncology, Soonchunhyang University Bucheon Hospital, Soonchunhyang University School of Medicine, 170 Jomaru-ro, Bucheon 14584, South Korea. skpark@schmc.ac.kr
Received: May 27, 2020
Peer-review started: May 25, 2020
First decision: September 14, 2020
Revised: September 25, 2020
Accepted: October 19, 2020
Article in press: October 19, 2020
Published online: November 6, 2020
Peer-review started: May 25, 2020
First decision: September 14, 2020
Revised: September 25, 2020
Accepted: October 19, 2020
Article in press: October 19, 2020
Published online: November 6, 2020
Core Tip
Core Tip: Choriocarcinoma is an extremely rare germ cell tumor and responds poorly to standard chemotherapy. Etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine regimen is widely used to treat gestational trophoblastic tumors in females, however, its role in choriocarcinoma of males is seldom reported. This case report is the first of its kind demonstrating successful treatment using the etoposide, methotrexate, actinomycin D, cyclophosphamide, and vincristine regimen in a male diagnosed with cisplatin-refractory high-risk nonseminomatous germ cell tumors.